Triple-positive breast cancer is uniquely defined by the concurrent expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), each playing a distinct role in tumor growth and survival. This evidence concerns the gene ESR1 and neoplasm.